Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 7;30(3):3102-3110.
doi: 10.3390/curroncol30030235.

Safety and Accuracy of Sentinel Lymph Node Biopsy Alone in Clinically Node-Positive Patients Undergoing Upfront Surgery for Invasive Breast Cancer: A Systematic Review

Olivia Lovrics  1 , Brendan Tao  2 , Elena Parvez  1   3
Affiliations

Safety and Accuracy of Sentinel Lymph Node Biopsy Alone in Clinically Node-Positive Patients Undergoing Upfront Surgery for Invasive Breast Cancer: A Systematic Review

Olivia Lovrics et al. Curr Oncol. .

Abstract

Landmark trials (Z0011 and AMAROS) have demonstrated that axillary lymph node dissection (ALND) can be safely omitted in patients with breast cancer and 1-2 positive sentinel nodes. Extrapolating from these and other cardinal studies such as NSABP B-04, guidelines state that patients with 1-2 needle biopsy-proven positive lymph nodes undergoing upfront surgery can have sentinel lymph node biopsy (SLNB) alone. The purpose of this study is to systematically review the literature to identify studies examining the direct application of SLNB in such patients. EMBASE and Ovid MEDLINE were searched from inception to 3 May 2022. Studies including patients with nodal involvement confirmed on pre-operative biopsy and undergoing SLNB were identified. Studies with neoadjuvant chemotherapy were excluded. Search resulted in 2518 records, of which 68 full-text studies were reviewed, ultimately yielding only 2 studies meeting inclusion criteria. Both studies used targeted axillary surgery (TAS) with pre-operative localization of the biopsy-proven positive node in addition to standard SLNB techniques. In a non-randomized single-center prospective study, Lee et al. report no regional recurrences in patients undergoing TAS or ALND, and no difference in distant recurrence or mortality at 5 years. In the prospective multicenter TAXIS trial by Webber et al., the median number of positive nodes retrieved with TAS in patients undergoing upfront surgery was 2 (1, 4 IQR). Within the subset of patients who underwent subsequent ALND, 61 (70.9%) had additional positive nodes, with 26 (30.2%) patients having ≥4 additional positive nodes. Our review demonstrates that there is limited direct evidence for SLNB alone in clinically node-positive patients undergoing upfront surgery. Available data suggest a high proportion of patients with residual disease in this setting. While the totality of the data, mostly indirect evidence, suggests SLNB alone may be safe, we call on clinicians and researchers to prospectively collect data on this patient population to better inform decision-making.

Keywords: axillary dissection; axillary surgery; de-escalation; sentinel lymph node biopsy; targeted axillary surgery.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA diagram.
See this image and copyright information in PMC

References

    1. Naoum G.E., Roberts S., Brunelle C.L., Shui A.M., Salama L., Daniell K., Gillespie T., Bucci L., Smith B.L., Ho A.Y., et al. Quantifying the impact of axillary surgery and nodal irradiation on breast cancer-related lymphedema and local tumor control: Long-term results from a prospective screening trial. J. Clin. Oncol. 2020;38:3430–3438. doi: 10.1200/JCO.20.00459. - DOI - PMC - PubMed
    1. McEvoy M.P., Gomberawalla A., Smith M., Boccardo F.M., Holmes D., Djohan R., Thiruchelvam P., Klimberg S., Dietz J., Feldman S. The prevention and treatment of breast cancer—related lymphedema: A review. Front. Oncol. 2022;12:1–12. doi: 10.3389/fonc.2022.1062472. - DOI - PMC - PubMed
    1. Galimberti V., Ribeiro Fontana S.K., Vicini E., Morigi C., Sargenti M., Corso G., Magnoni F., Intra M., Veronesi P. “This house believes that: Sentinel node biopsy alone is better than TAD after NACT for cN+ patients”. Breast. 2023;67:21–25. doi: 10.1016/j.breast.2022.12.010. - DOI - PMC - PubMed
    1. Krag D.N., Anderson S.J., Julian T.B., Brown A.M., Harlow S.P., Costantino J.P., Ashikaga T., Weaver D.L., Mamounas E.P., Jalovec L.M., et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–933. doi: 10.1016/S1470-2045(10)70207-2. - DOI - PMC - PubMed
    1. Miranda K., Pace D., Cintron R., Rodrigues J.C.F., Fang J., Smith A., Rohloff P., Coelho E., De Haas F., Souza D., et al. IBCSG 23-01 randomised controlled trial comparing axillary dissection versus no axillary dissection in patients with sentinel node micrometastases. Lancet Oncol. 2011;76:1358–1375. doi: 10.1016/S1470-2045(13)70035-4.IBCSG. - DOI

Publication types